SCHEMBL22684241

SCHEMBL22684241

CC1(O)CN(C(=O)c2ccncc2Br)C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
SLC6A9 P48067 1/20 0.36
L3MBTL3 Q96JM7 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAP2K2 P36507 1/20 0.36
MAP2K1 Q02750 1/20 0.36
VNN1 O95497 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
MBTD1 Q05BQ5 1/20 0.34
PKM P14618 1/20 0.34
ALDH1A1 P00352 1/20 0.34
JAK2 O60674 1/20 0.34
NTRK1 P04629 1/20 0.34
PDE10A Q9Y233 1/20 0.34
KDM4C Q9H3R0 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684100 0.84 GAA (0.41) GAASLC6A9MEN1KMT2APDE10A
SCHEMBL22683855 0.78 GAA (0.44) GAAL3MBTL3L3MBTL1MEN1KMT2A
SCHEMBL10272980 0.78 GAA (0.47) GAAL3MBTL3L3MBTL1MEN1KMT2A
SCHEMBL782625 0.70 CCNC (0.43) GAASLC6A9L3MBTL1MEN1KMT2A
SCHEMBL31407215 0.70 CCNC (0.43) GAASLC6A9L3MBTL1MEN1KMT2A
SCHEMBL24691857 0.68 HPGD (0.58) L3MBTL3L3MBTL1KMT2A
SCHEMBL480991 0.68 KDM4C (0.59) GAAL3MBTL1MEN1KMT2ACCNC
SCHEMBL29920601 0.68 KDM4C (0.59) GAAL3MBTL1MEN1KMT2ACCNC
SCHEMBL5700120 0.67 TDP1 (0.55) GAAL3MBTL1MAP2K1MEN1KMT2A
SCHEMBL25207609 0.67 CCNC (0.43) GAAL3MBTL1MEN1KMT2ACCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3740478-B1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-11-01 EP disclosed
CN-111601799-B Fused imidazole derivatives as Il-17 modulators UCB生物制药有限责任公司 2023-06-09 CN disclosed
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators UCB Biopharma SRL (BE) 2022-10-18 US disclosed
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators UCB Biopharma SRL (BE) 2021-02-25 US disclosed
EP-3740478-A1 FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2020-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472794-B2 Fused imidazole derivatives as IL-17 modulators IL17A, IL2, IL23R GAA 3670/4885SLC6A9 4755/4885L3MBTL3 3231/4885
US-20210053952-A1 Fused Imidazole Derivatives as IL-17 Modulators IL17A, IL2, IL23R GAA 3670/4885SLC6A9 4755/4885L3MBTL3 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.